Neurochemical Research

, Volume 21, Issue 10, pp 1209–1212 | Cite as

Increased acetylcholinesterase activity in selected regions of rat brain after chronic (−)-Deprenyl administration

  • Madepalli K. Lakshmana
  • S. Jagadeesh
  • M. N. Subhash
Original Articles


(−)-Deprenyl, 0.05, 1.0, 2.0, and 10.0 mg/kg body weight, was administered intraperitonially to Wistar rats for 30 days. The activity of acetylcholinesterase, and monoamine oxidase A and B were assayed in different brain regions. After the experimental period acetyl cholinesterase activity was found to be significantly increased in frontal cortex [P<0.001] and hippocampus [P<0.001] but not in striatum and brainstem at 0.1, 1.0, and 2.0 mg/kg dose, the maximum increase being at 0.1 mg/kg dose. Monoamine oxidase B activity was inhibited by more than 90% at 1.0, 2.0, and 10.0 mg/kg dose while 0.05 and 0.1 dose inhibited only about 55% and 70% respectively. Monoamine oxidase A activity was inhibited to more than 70% at 1.0 mg dose and to more than 90% at 2.0 and 10.0 mg/kg dose. At 0.05 and 0.1 mg/kg dose monoamine oxidase A activity was not significantly altered.

Key Words

(−)-Deprenyl rat brain regions AChE MAO-A MAO-B 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Parkinson study group. 1993. Effect of tocopherol and (−) deprenyl to the progression of disability in early Parkinson's disease. N. Engl. J. Med. 328:176–183.CrossRefGoogle Scholar
  2. 2.
    Piccinin, G. L., Finali, G., and Piccirilli, M. 1990. Neurosychological effects of L-deprenyl in Alzheimer's type dementia. Clin. Neuropharmacology 13:147–163.Google Scholar
  3. 3.
    Mann, J. J., Aarons, S. F., and Wilner, P. J. 1989. A controlled study of the antidepressant efficacy and side effects of (−) deprenyl. Arch. Gen. Psychiatry 46:45–54.PubMedGoogle Scholar
  4. 4.
    Finnegan, K. T., Skratt, J. J., Irwin, I., De Lanney, L. E., and Langston, J. W. 1990. Protection against DSP-4 induced neurotoxicity by (−) deprenyl is not related to its inhibition of MAO-B. Eur. J. Pharmacol. 184:119–126.PubMedCrossRefGoogle Scholar
  5. 5.
    Kitani, S., Kanai, S., Sato, Y., Ohta, M., Ivy, G. O., and Carrillo, M-C. 1992. Chronic treatment of (−) deprenyl prolongs the life span of male Fisher 344 rats. Further evidence Life Sci. 52:281–288.CrossRefGoogle Scholar
  6. 6.
    Knoll, J. 1988. The striatal dopamine dependency of life span in male rats. Longevity with (−) deprenyl. Mech. Aging Dev. 46: 237–242.PubMedCrossRefGoogle Scholar
  7. 7.
    Knoll, J., and Miklya, Y. N. 1994. Sexually low performing male rats die earlier than their high performing peers and (−) deprenyl treatment eliminates this difference. Life Sci. 54:1047–1057.PubMedCrossRefGoogle Scholar
  8. 8.
    Piccinin, G. L., Finali, G., and Piccirilli, M. 1990. Neuropsychological effects of L-deprenyl in Alzheimers type dementia. Clin. Neuropharmacology 13:147–163.CrossRefGoogle Scholar
  9. 9.
    Tariot, P. N., Sunderland, T., Weingarther, H., Murphy, D. L., Welkowitz, J. A., Thompson, K., and Cohen, R. M. 1987. Cognitive effects of L-deprenyl in Alzheimer's disease. Psychopharmacology 91:489–495.PubMedCrossRefGoogle Scholar
  10. 10.
    Peterson, I. A., Juorio, A. V., Berry, M. D., and Zhu, M. Y. 1991. Inhibition of monoamine oxidase-B by (−) deprenyl potentiates neuronal responses to dopamine agonists but does not inhibit dopamine catabolism in rat striatum. J. Pharmacol. Exp. Therap. 258: 1019–1026.Google Scholar
  11. 11.
    Cohen, G., and Spina, M. B. 1989. (−) Deprenyl suppresses the oxidant stress associated with increased dopamine turnover. Ann. Neurol. 26:689–690.PubMedCrossRefGoogle Scholar
  12. 12.
    Langston, J. W. 1988. Pages 75–85 in Jankevic J (ed.) Parkinson's disease and movement disorders. Baltimore, urban and schwarzenberg.Google Scholar
  13. 13.
    Carrillo, M. C., Kanai, S., Nokubo, M., Ivy, G. V., Sato, Y., and Kitani, K. 1992. (−) Deprenyl increases activities of superoxide dismutase and catalase in striatum but not hippocampus: The sex and age related differences in the optimal dose in the rat. Exp. Neurol. 116:286–294.PubMedCrossRefGoogle Scholar
  14. 14.
    Inestrosa, N. C., and Sato, C. 1992. Molecular biology of the amyloid of Alzheimer's disease: an overview. Biol. Res. 25:63–72.PubMedGoogle Scholar
  15. 15.
    Dunnett, S. B. and Fibiger, H. C. 1993. Role of forebrain cholinergic systems in learning and memory: relevance to the cognitive deficits of aging and Alzheimer's dementia. In Cholinergic function and dysfunction. Progress in Brain Research, (ed. Cuello, A. C.) pp 413–420, Elsevier, Amsterdam.Google Scholar
  16. 16.
    Fishman, E. B., Siek, G. C., Mc Callum, R. D., Bird, E. D., Volicer, L. and Marquis, J. K. 1986. Distribution of the molecular forms of acetyl cholinesterase in human brain: alterations in dementia of the Alzheimer's type. Ann. Neurol. 19:246–252.PubMedCrossRefGoogle Scholar
  17. 17.
    Lindgren, S., Anden N. E. and Anden, M. G. 1982. A fluorometric method for determination of GABA in tissues following cation exchange chromatography and condensation with 0-phthalaldehyde. J. Neural Transm. 55:243–252.CrossRefGoogle Scholar
  18. 18.
    Ellman, G. L., Gourtney, K. D., Valentino, A. Jr. and Featherstone, R. M. 1961. A new and rapid colorimetric determination of acetyl cholinesterase activity. Biochem. Pharmacol. 7:78–95.CrossRefGoogle Scholar
  19. 19.
    Naoi, M. and Nagatsu, T. 1986. Inhibition of monoamine oxidase by 3,4-Dihydroxyphenylserine. J. Neurochem. 47:604–607.PubMedGoogle Scholar
  20. 20.
    Bradford, M. M. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:248–254.PubMedCrossRefGoogle Scholar
  21. 21.
    Knoll, B., Held, G., and Gyarmati, Z. (1977) The effect of selective MAO inhibitors on the conditioned avoidance response of wistar rats. Pol. J. Pharmacol. Pharm. 29:291–296.PubMedGoogle Scholar
  22. 22.
    Richfield, E. K., Young, A. B. and Penney, J. B. 1987. Comparative distribution of dopamine D1 and D2 receptors in the basal ganglia of turtles, pigeons, rats, cats and monkeys. J. Comp. Neurol. 262:446–463.PubMedCrossRefGoogle Scholar
  23. 23.
    Knoll, J. 1981. The pharmacology of selective MAO inhibitors. Pages 54–65, in Monoamine Oxidase Inhibitors—The state of the Art. Youdim M. B. H. and Payke, S (eds.), Wiley and Sons, Chicheste.Google Scholar
  24. 24.
    Bareggi, S. R., and Giacobini, F. 1978. Acetyl cholinesterase activity in ventricular and cisternal CSF of dogs: Effect of chlorpromazine. J. Neurosci. Res. 3:335–340.PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Publishing Corporation 1996

Authors and Affiliations

  • Madepalli K. Lakshmana
    • 2
  • S. Jagadeesh
    • 1
  • M. N. Subhash
    • 1
  1. 1.Department of NeurochemistryNational Institute of Mental Health and NeurosciencesBangaloreIndia
  2. 2.Department of NeurophysiologyNational Institute of Mental Health and NeurosciencesBangaloreIndia

Personalised recommendations